VSV-G lentiviral vectors – achieve success with the gold standard for engineered T cell therapy

Our proprietary vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped lentiviral vector (LVV) platform is based on a third-generation system that further improves the safety and efficiency of gene delivery. It delivers LVV of consistently high quality and has supported well over 100 different therapeutic projects. Leveraging our proven expertise, we support your journey from early development to late-stage and commercialized products with confidence and speed.

Expertise you can trust

96% success rate on over 400 batches*

Experience and success across many construct types & sizes, including CAR, dual CAR, and TCR

7 late stage programs, 1 commercially approved product

^{*Based on data collected through 2024. Miltenyi Biotec does not guarantee any specific results, or that batches will fully conform with any particular specifications. Individual success rate may vary based on factors such as client specifications.}

Leverage our VSV-G LVV platform to maximize the performance of your engineered T cells

VSV-G LVV delivered to 28+ countries
10+ years of expertise that will get you to the finish line
Seamless scaling from preclinical to commercial production

Illustration showing the comparison of transducing titers between client plasmids vs. Miltenyi-optimized designs

Comparing client plasmids vs. Miltenyi-optimized designs: superior transducing titers.

Miltenyi Bioindustry: optimized plasmids, superior performance

Boost your plasmid design with Miltenyi Bioindustry. Our optimization enhances transducing titer, improving therapy performance and reducing costs.

What you can expect:

All raw materials, equipment, validated analytics, and GMP documentation is pre-defined & available
Research-grade & preclinical vector for clinical trial enabling studies
From preclinical to GMP lentiviral vector in as little as 8.5 months*
Regulatory support through Regulatory Master File or Regulatory Support File

^{*Based on data collected through 2024. Miltenyi Biotec does not guarantee that any specific delivery date(s) will be met. Individual timelines may vary based on factors such as client’s stage of development and specifications.}

Interested in more information? Get the details!

Webinar

Lentiviral vector development & manufacturing: an established platform process

Webinar

Lessons learned on commercializing LVV as a drug substance

Further information

Lentiviral vector platform

Questions? Want to know more?
Fill out our form to get in touch with our experts.

Contact us

Privacy Settings

VSV-G lentiviral vectors – achieve success with the gold standard for engineered T cell therapy

Expertise you can trust

96% success rate on over 400 batches*

Experience and success across many construct types & sizes, including CAR, dual CAR, and TCR

7 late stage programs, 1 commercially approved product

Leverage our VSV-G LVV platform to maximize the performance of your engineered T cells

Miltenyi Bioindustry: optimized plasmids, superior performance

What you can expect:

Interested in more information? Get the details!

Webinar

Webinar

Further information

Lentiviral vector platform

Questions? Want to know more?Fill out our form to get in touch with our experts.

Questions? Want to know more?
Fill out our form to get in touch with our experts.